High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system

Leuk Lymphoma. 2016 Aug;57(8):1961-4. doi: 10.3109/10428194.2015.1120867. Epub 2016 Jan 4.

Authors

Richard C Curry¹, Geraldine Faivre¹, Leila Akkari², Johanna A Joyce², Oscar Lin³, Marc Rosenblum³, Eli L Diamond¹, Rebecca Fisher⁴, Antonio Omuro¹

Affiliations

¹ a Department of Neurology , Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
² b Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
³ c Department of Pathology , Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
⁴ d Department of Neurology , Mount Sinai Hospital , New York , NY , USA.

PMID: 26727454
DOI: 10.3109/10428194.2015.1120867

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Central Nervous System Neoplasms / diagnosis
Central Nervous System Neoplasms / drug therapy*
Dose-Response Relationship, Drug
Fatal Outcome
Female
Histiocytic Sarcoma / diagnosis
Histiocytic Sarcoma / drug therapy*
Humans
Methotrexate / administration & dosage
Middle Aged
Remission Induction

Substances

Methotrexate